Answers are grounded in this paper and cite their sources.
This Primer proposes a structured framework for prioritizing genetic variants for animal modeling in rare disease. Drawing on the experience of the Congenital Anomalies Cluster of the UK MRC National Mouse Genetics Network (NMGM), we outline a three-step process: first, rigorous curation of clinical, molecular, and functional evidence to establish biological plausibility and define a mechanistic hypothesis; second, assessment and selection of the most appropriate model capable of addressing the question; and third, integration of practical and ethical considerations, prioritizing variants with clinical actionability, stronger cohorts, and mechanistic potential.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: